Approvals aren’t enough; Big Pharma R&D restructuring will continue

John Carroll Here's a perennial favorite among the top trends in the industry. About six years ago, most of Big Pharma got serious about one of its biggest problems: they ...

Roche builds CLL case for Gazyva in two-horse race with GSK

Emily Wasserman Roche won FDA approval for a supplemental license application of its chronic lymphocytic leukemia drug Gazyva, strengthening its case over rival GlaxoSmithKline and ...

Roche boosts its antibody arsenal with a $489M buyout

Damian Garde Roche is betting big on antibodies that can attack two targets at once, signing on to buy Austria's Dutalys for as much as $ 488.8 million and get its hands on some ...

GlaxoSmithKline CEO: Chin up, investors. Dividend’s safe, and Novartis deal awaits

Carly Helfand GlaxoSmithKline's shareholders may be expecting less-than-stellar sales next year as generics take their toll on respiratory behemoth Advair. But they still have plenty ...

Court’s decision on Namenda ‘hard switch’ could spill over into precedent

Tracy Staton Last week, a New York judge called a halt on Actavis' plan to pull Namenda off the market, throwing off its strategy for switching patients to a newer extended-release ...

Tetraphase spikes on a Phase III success for lead antibiotic

John Carroll Shares of Tetraphase Pharmaceuticals spiked 15% Wednesday afternoon after the biotech said its lead antibiotic hit its primary endpoint in a head-to-head Phase III study, ...

Salix expects lackluster sales as it speeds to fix inventory issues

Carly Helfand Back in November, Salix revealed some inventory issues that had skewed perceived demand for some of its products–and possibly cost it a deal with Allergan in the ...

Auspex’s Huntington’s drug hits the mark in Phase III

Damian Garde Auspex Pharmaceuticals' treatment for a movement disorder tied to Huntington's disease met its main goal in a late-stage study, the company said, clearing the way ...

Point-of-care marketing shoots past DTC as pharma’s latest marketing trend

Emily Wasserman Point-of-care marketing is shooting past direct-to-consumer advertising as pharma marketing's latest trend.  FiercePharma News

Google Ventures splashes into life sciences with its $425M purse

Damian Garde Google Ventures is betting more and more on life sciences startups each year, and the well-funded financier tells The Wall Street Journal that's not going to change ...

Billionaire Soon-Shiong dives into immuno-oncology with $20M Sorrento venture

Damian Garde Patrick Soon-Shiong, billionaire physician and biotech entrepreneur, wants in on the hottest field in oncology, forming a joint venture with Sorrento Therapeutics to develop ...

Bayer runs into another German roadblock in marketing vision drug Eylea

Tracy Staton Germany's cost-effectiveness watchdog said Bayer eye drug Eylea doesn't perform any better than its Novartis rival, Lucentis, as a treatment for diabetic macular ...
Page 1 of 3123
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS